CCL21 induces extensive intratumoral immune cell infiltration and specific anti-tumor cellular immunity

Heth R. Turnquist, Xuede Lin, Abdelkader E. Ashour, Michael A Hollingsworth, Rakesh K Singh, James E Talmadge, Joyce C Solheim

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Chemokines are vital messengers that regulate immune cell activity. The chemokine CCL21 is normally expressed in secondary lymphoid organs and acts as a chemoattractant for several populations of immune cells. Herein, we report that intratumoral CCL21 administration recruited significant numbers of immune cells into murine pancreatic tumors and inhibited tumor growth. Detailed flow cytometric and confocal analysis of CCL21-treated tumor cell isolates revealed increased lymphoid-related dendritic cells (lDC) and myeloid DC (mDC), naïve and mature T cells, natural killer (NK) cells, and NKT cells infiltrating the tumor mass. Furthermore, CCL21 intratumoral treatments resulted in significant tumor growth inhibition in wild-type (WT) C57BL/6 mice, but no therapeutic benefit was observed in C57BL/6 RAG2-/-Pfp-/- mice, suggesting that the growth inhibition observed was immunologically mediated. CCL21 intratumoral injections generated immune responses that were tumor-specific and that could be transferred to naïve animals via splenocytes. In addition, intratumoral injection of CCL21 into pancreatic tumors reduced the growth of distant tumors as well as treated tumors. Thus, these data demonstrate in a pancreatic tumor model that intratumoral administration of CCL21 can cause significant immune cell infiltration of the tumor mass, delay growth of treated tumors, and generate a tumor-specific cellular immune response.

Original languageEnglish (US)
Pages (from-to)631-639
Number of pages9
JournalInternational journal of oncology
Volume30
Issue number3
StatePublished - Mar 1 2007

Fingerprint

Cellular Immunity
Neoplasms
Growth
Chemokine CCL21
Natural Killer T-Cells
Injections
Chemotactic Factors
Inbred C57BL Mouse
Chemokines
Natural Killer Cells
Dendritic Cells
Cell Count
T-Lymphocytes

Keywords

  • CCL21
  • Chemokine
  • Dendritic cell
  • Pancreatic cancer
  • Tumor immunology

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

CCL21 induces extensive intratumoral immune cell infiltration and specific anti-tumor cellular immunity. / Turnquist, Heth R.; Lin, Xuede; Ashour, Abdelkader E.; Hollingsworth, Michael A; Singh, Rakesh K; Talmadge, James E; Solheim, Joyce C.

In: International journal of oncology, Vol. 30, No. 3, 01.03.2007, p. 631-639.

Research output: Contribution to journalArticle

@article{b685e31d04b140d1a5bec651753a00af,
title = "CCL21 induces extensive intratumoral immune cell infiltration and specific anti-tumor cellular immunity",
abstract = "Chemokines are vital messengers that regulate immune cell activity. The chemokine CCL21 is normally expressed in secondary lymphoid organs and acts as a chemoattractant for several populations of immune cells. Herein, we report that intratumoral CCL21 administration recruited significant numbers of immune cells into murine pancreatic tumors and inhibited tumor growth. Detailed flow cytometric and confocal analysis of CCL21-treated tumor cell isolates revealed increased lymphoid-related dendritic cells (lDC) and myeloid DC (mDC), na{\"i}ve and mature T cells, natural killer (NK) cells, and NKT cells infiltrating the tumor mass. Furthermore, CCL21 intratumoral treatments resulted in significant tumor growth inhibition in wild-type (WT) C57BL/6 mice, but no therapeutic benefit was observed in C57BL/6 RAG2-/-Pfp-/- mice, suggesting that the growth inhibition observed was immunologically mediated. CCL21 intratumoral injections generated immune responses that were tumor-specific and that could be transferred to na{\"i}ve animals via splenocytes. In addition, intratumoral injection of CCL21 into pancreatic tumors reduced the growth of distant tumors as well as treated tumors. Thus, these data demonstrate in a pancreatic tumor model that intratumoral administration of CCL21 can cause significant immune cell infiltration of the tumor mass, delay growth of treated tumors, and generate a tumor-specific cellular immune response.",
keywords = "CCL21, Chemokine, Dendritic cell, Pancreatic cancer, Tumor immunology",
author = "Turnquist, {Heth R.} and Xuede Lin and Ashour, {Abdelkader E.} and Hollingsworth, {Michael A} and Singh, {Rakesh K} and Talmadge, {James E} and Solheim, {Joyce C}",
year = "2007",
month = "3",
day = "1",
language = "English (US)",
volume = "30",
pages = "631--639",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "3",

}

TY - JOUR

T1 - CCL21 induces extensive intratumoral immune cell infiltration and specific anti-tumor cellular immunity

AU - Turnquist, Heth R.

AU - Lin, Xuede

AU - Ashour, Abdelkader E.

AU - Hollingsworth, Michael A

AU - Singh, Rakesh K

AU - Talmadge, James E

AU - Solheim, Joyce C

PY - 2007/3/1

Y1 - 2007/3/1

N2 - Chemokines are vital messengers that regulate immune cell activity. The chemokine CCL21 is normally expressed in secondary lymphoid organs and acts as a chemoattractant for several populations of immune cells. Herein, we report that intratumoral CCL21 administration recruited significant numbers of immune cells into murine pancreatic tumors and inhibited tumor growth. Detailed flow cytometric and confocal analysis of CCL21-treated tumor cell isolates revealed increased lymphoid-related dendritic cells (lDC) and myeloid DC (mDC), naïve and mature T cells, natural killer (NK) cells, and NKT cells infiltrating the tumor mass. Furthermore, CCL21 intratumoral treatments resulted in significant tumor growth inhibition in wild-type (WT) C57BL/6 mice, but no therapeutic benefit was observed in C57BL/6 RAG2-/-Pfp-/- mice, suggesting that the growth inhibition observed was immunologically mediated. CCL21 intratumoral injections generated immune responses that were tumor-specific and that could be transferred to naïve animals via splenocytes. In addition, intratumoral injection of CCL21 into pancreatic tumors reduced the growth of distant tumors as well as treated tumors. Thus, these data demonstrate in a pancreatic tumor model that intratumoral administration of CCL21 can cause significant immune cell infiltration of the tumor mass, delay growth of treated tumors, and generate a tumor-specific cellular immune response.

AB - Chemokines are vital messengers that regulate immune cell activity. The chemokine CCL21 is normally expressed in secondary lymphoid organs and acts as a chemoattractant for several populations of immune cells. Herein, we report that intratumoral CCL21 administration recruited significant numbers of immune cells into murine pancreatic tumors and inhibited tumor growth. Detailed flow cytometric and confocal analysis of CCL21-treated tumor cell isolates revealed increased lymphoid-related dendritic cells (lDC) and myeloid DC (mDC), naïve and mature T cells, natural killer (NK) cells, and NKT cells infiltrating the tumor mass. Furthermore, CCL21 intratumoral treatments resulted in significant tumor growth inhibition in wild-type (WT) C57BL/6 mice, but no therapeutic benefit was observed in C57BL/6 RAG2-/-Pfp-/- mice, suggesting that the growth inhibition observed was immunologically mediated. CCL21 intratumoral injections generated immune responses that were tumor-specific and that could be transferred to naïve animals via splenocytes. In addition, intratumoral injection of CCL21 into pancreatic tumors reduced the growth of distant tumors as well as treated tumors. Thus, these data demonstrate in a pancreatic tumor model that intratumoral administration of CCL21 can cause significant immune cell infiltration of the tumor mass, delay growth of treated tumors, and generate a tumor-specific cellular immune response.

KW - CCL21

KW - Chemokine

KW - Dendritic cell

KW - Pancreatic cancer

KW - Tumor immunology

UR - http://www.scopus.com/inward/record.url?scp=33947722716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947722716&partnerID=8YFLogxK

M3 - Article

C2 - 17273764

AN - SCOPUS:33947722716

VL - 30

SP - 631

EP - 639

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 3

ER -